Google
Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.
Shares of Replimune Group receive multiple downgrades after the Food and Drug Administration twice rejects its experimental cancer drug.
Continue Reading
Get personalized investment ideas from AI Coach, manage and analyze your own Portfolio & Watchlist, and receive dedicated support when you need account assistance.
Continue with FacebookUser not found.
Shares of Replimune Group receive multiple downgrades after the Food and Drug Administration twice rejects its experimental cancer drug.
Continue Reading
